Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.60 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.60 |
| ▸ | HPGD | P15428 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | GGT1 | P19440 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspirin SCHEMBL11851702 | 1.00 | KDM4E (0.60) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL29743139 | 1.00 | KDM4E (0.60) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL25878 | 1.00 | KDM4E (0.60) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL4834297 | 1.00 | KDM4E (0.60) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL19030830 | 0.96 | KDM4E (0.56) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL29743138 | 0.96 | KDM4E (0.56) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL408904 | 0.96 | KDM4E (0.56) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL2993825 | 0.96 | KDM4E (0.61) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL2993829 | 0.96 | KDM4E (0.61) | KDM4EHSD17B10HPGDALDH1A1TDP1 | |
| Aspirin SCHEMBL4094492 | 0.94 | KDM4E (0.53) | KDM4EHSD17B10HPGDALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3397 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073250-A1 | Improved synthesis of lysine acetylsalicylate - Glycine particles | ASPIAIR GMBH (DE) | 2025-03-06 | — | — | US | claimed |
| EP-4460487-A1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | AspiAir GmbH (DE) | 2024-11-13 | — | — | EP | claimed |
| US-20240041935-A1 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2024-02-08 | — | — | US | claimed |
| EP-3305300-B1 | INTRAVITREAL LYSINE ACETYLSALICYLATE FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | FUNDACION PARA EL FOMENTO DE LA INVESTIG SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA (ES) | 2023-10-04 | — | — | EP | claimed |
| WO-2023131645-A1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | ASPIAIR GMBH (DE) | 2023-07-13 | — | — | WO | claimed |
| CN-116063580-A | Peptide analogues | 艾得佩索拉公司 | 2023-05-05 | — | — | CN | claimed |
| CN-112305138-B | Method for simultaneously determining content of lysine and glycine | 蚌埠丰原医药科技发展有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115607516-A | Medicine for preventing and treating cold or viral diseases | 刘力 | 2023-01-17 | — | — | CN | claimed |
| CN-115607556-A | Medicine for preventing and treating asthma, chronic obstructive pulmonary disease, allergic diseases, etc | 刘力 | 2023-01-17 | — | — | CN | claimed |
| CN-110114333-B | Improved synthesis of lysine acetylsalicylate glycine particles | 阿斯皮亚尔股份有限公司 | 2022-12-02 | — | — | CN | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| CN-1125094-A | Compound lysinpirinum nose drops and preparing method thereof | CAO BAOCHUN (CN) | 1996-06-26 | — | — | CN | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| CN-1078888-A | The manufacture method of aspisol | EXPERIMENT FACTORY OF BENGFU C (CN) | 1993-12-01 | — | — | CN | claimed |
| US-4988683-A | Administering lysine acetylsalicylate by mouth for pain and hypothermia | CORBIERE JEROME (FR) | 1991-01-29 | — | — | US | claimed |
| US-4885288-A | Pharmaceutical compositions containing lysine acetylsalicylate | SYNTHELABO (FR) | 1989-12-05 | — | — | US | claimed |
| EP-0214881-B1 | PHARMACEUTICAL COMPOSITIONS ON THE BASIS OF DILTIAZEM AND ASPIRIN | SYNTHELABO (FR) | 1989-09-27 | — | — | EP | claimed |
| US-4806530-A | ANTICOAGULANT | SYNTHELABO (FR) | 1989-02-21 | — | — | US | claimed |
| EP-0293563-A1 | Combined preparation, especially against inflammatory processes | OXO-Chemie GmbH (DE) | 1988-12-07 | — | — | EP | claimed |
| WO-1988006889-A1 | COMBINED PREPARATION, PARTICULARLY TO COMBAT INFLAMMATORY PROCESSES | OXO CHEMIE GMBH (DE) | 1988-09-22 | — | — | WO | claimed |